Calidi Biotherapeutics, Inc. (CLDI)
0.6993
+0.02
(+2.99%)
USD |
NYAM |
Nov 06, 10:23
Calidi Biotherapeutics Enterprise Value : -0.9339M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | -0.9339M |
| November 04, 2026 | -0.8278M |
| November 03, 2026 | -0.7881M |
| November 02, 2026 | -0.9776M |
| October 30, 2026 | -0.9152M |
| October 29, 2026 | -0.9491M |
| October 28, 2026 | -0.8864M |
| October 27, 2026 | -0.9735M |
| October 26, 2026 | -1.015M |
| October 23, 2026 | -1.005M |
| October 22, 2026 | -0.9945M |
| October 21, 2026 | -0.7486M |
| October 20, 2026 | -0.7444M |
| October 19, 2026 | -0.7165M |
| October 16, 2026 | -0.6049M |
| October 15, 2026 | -0.5359M |
| October 14, 2026 | -0.5278M |
| October 13, 2026 | -0.4739M |
| October 12, 2026 | -0.3697M |
| October 09, 2026 | -0.2029M |
| October 08, 2026 | -0.1821M |
| October 07, 2026 | -0.2446M |
| October 06, 2026 | -0.2237M |
| October 05, 2026 | -0.1613M |
| October 02, 2026 | -0.0988M |
| Date | Value |
|---|---|
| October 01, 2026 | -0.0988M |
| September 30, 2026 | -0.1196M |
| September 29, 2026 | -0.0988M |
| September 28, 2026 | -0.1196M |
| September 25, 2026 | 0.0053M |
| September 24, 2026 | 0.1511M |
| September 23, 2026 | -0.078M |
| September 22, 2026 | -0.0363M |
| September 21, 2026 | -0.0315M |
| September 18, 2026 | -0.0571M |
| September 17, 2026 | 0.2969M |
| September 16, 2026 | 0.0886M |
| September 15, 2026 | 0.0886M |
| September 14, 2026 | 0.1928M |
| September 11, 2026 | 0.2344M |
| September 10, 2026 | 0.3802M |
| September 09, 2026 | 0.4843M |
| September 08, 2026 | 0.4635M |
| September 04, 2026 | 0.5364M |
| September 03, 2026 | 0.4635M |
| September 02, 2026 | 0.4427M |
| September 01, 2026 | 0.4219M |
| August 31, 2026 | 0.4427M |
| August 28, 2026 | 0.401M |
| August 27, 2026 | 0.3594M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.884B |
| Oncolytics Biotech, Inc. | 52.27M |
| Sangamo Therapeutics, Inc. | 38.97M |
| Sarepta Therapeutics, Inc. | 2.113B |
| Anixa Biosciences, Inc. | 89.83M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.16M |
| Total Expenses (Quarterly) | 4.16M |
| EPS Diluted (Quarterly) | -2.938 |
| Earnings Yield | -7.73K% |
| Normalized Earnings Yield | -7726.24 |